Current and emerging drugs for acute bacterial skin and skin structure infections: an update

Bibliography

• Moran GJ, Abrahamian FM, Lovecchio F, et al. Acute bacterial skin. infections: developments Since the 2005 Infectious Diseases Society of America (IDSA) Guidelines. J Emerg Med 2013;44:e397-412
   PubMedGoogle Scholar
• Burke SL, Rose WE. New pharmacological treatments for methicillin-resistant infections. Expert Opin Pharmacother 2014;15:1-9
   PubMedGoogle Scholar
• Kujath P, Kujath C. Complicated skin, skin structure and soft tissue infections - Are we threatened by multi-resistant pathogens? Eur J Med Res 2010;15:544-53
   PubMed Web of Science ®Google Scholar
• Ray G, Suaya J, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis 2013;13:252
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Future gazing in the management of multiply drug-resistant Gram-positive infection. J Infect 2009;59(Suppl 1):S75-80
   PubMedGoogle Scholar
• Watkins RR, David MZ, Salata RA. Current concepts on the virulence mechanisms of methicillin-resistant Staphylococcus aureus. J Med Microbiol 2012;61:1179-93
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Mcconeghy KW. Methicillin-resistant staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 2013;58(Suppl 1):S20-7
   Google Scholar
• Stevens DL. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. J Infect 2009;59:S32-9
   PubMed Web of Science ®Google Scholar
• Rybak JM, Barber KE, Rybak MJ. Current and prospective treatments for multidrug-resistant Gram-positive infections. Expert Opin Pharmacother 2013;14:1919-32
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Peterson D L. New Gram-positive antibiotics: better than vancomycin? Curr Opin Infect Dis 2011;24:515-20
   PubMed Web of Science ®Google Scholar
• Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistantstaphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc 2011;86:1230-43
   PubMed Web of Science ®Google Scholar
• Napolitano LM. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt) 2008;9(Suppl 1):s17-27
   PubMedGoogle Scholar
• Bassetti M, Baguneid M, Bouza E, et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 2014;20:3-18
   PubMed Web of Science ®Google Scholar
• Liu C, Talan DA, Cosgrove SE, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Disease Society of America. Clin Infect Dis 2014;59:e10-52
   PubMed Web of Science ®Google Scholar
• Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010;15:554-63
   PubMed Web of Science ®Google Scholar
• Liapikou A, Torres A. Emerging drugs on methicillin-resistant. Expert Opin Emerg Drugs 2013;18:291-305
   PubMed Web of Science ®Google Scholar
• Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23:99-139
   PubMed Web of Science ®Google Scholar
• Avent ML, Vaska VL, Rogers BA, et al. Vancomycin therapeutics and monitoring: a contemporary approach. Int Med J 2013;43:110-19
   Google Scholar
• Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clin Infect Dis 2006;42:S35-9
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer J, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-System Pharmacists, and The Society Of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7
   PubMed Web of Science ®Google Scholar
• Vandecasteele SJ, Vriese AS, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 2013;68:743-8
   PubMed Web of Science ®Google Scholar
• O’Brien DJ, Gould IM. Does vancomycin have a future in the treatment of skin infections? Curr Opin Infect Dis 2014;27:146-54
   PubMed Web of Science ®Google Scholar
• Peppard WJ, Weigelt JA. Role of linezolid in the treatment of complicated skin and soft tissue infections. Expert Rev Anti Infect Ther 2006;4:357-66
   PubMedGoogle Scholar
• Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2013;9:103-66
   Google Scholar
• Hair P, Keam S. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 2007;67:1483-512
   PubMed Web of Science ®Google Scholar
• Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65:iii35-44
   PubMed Web of Science ®Google Scholar
• Robbel L, Marahiel MA. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J Biol Chem 2010;285:27501-8
   PubMed Web of Science ®Google Scholar
• White B, Seaton R. Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist 2011;4:115-27
   PubMedGoogle Scholar
• Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013;75:331-6
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55:1162-72
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-709
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1963-71
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich A-B, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44
   PubMed Web of Science ®Google Scholar
• Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010;30:80-94
   PubMed Web of Science ®Google Scholar
• Saravolatz L, Stein G, Johnson L. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009;49:1908-14
   PubMed Web of Science ®Google Scholar
• Chang MH, Kish TD, Fung HB. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria in adults. Clin Ther 2010;32:2160-85
   PubMed Web of Science ®Google Scholar
• Polyzos KA, Mavros M, Vardakas KZ, et al. Efficacy and Safety of Telavancin in Clinical Trials: a Systematic Review and Meta-Analysis. PLoS One 2012;7:e41870
   PubMed Web of Science ®Google Scholar
• Goodman J, Martin S. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag 2012;8:149-56
   PubMed Web of Science ®Google Scholar
• Casapao AM, Steed ME, Levine DP, et al. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opin Pharmacother 2012;13:1177-86
   PubMed Web of Science ®Google Scholar
• Lodise TP, Low DE. CeftarolineFosamil in the Treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 2012;72:1473-93
   PubMed Web of Science ®Google Scholar
• Corey G, Wilcox M, Talbot G, et al. Integrated analysis of CANVAS. 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;5:641-50
   Google Scholar
• Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant staphylococcus aureus. Clin Infect Dis 2011;52:1156-63
   PubMed Web of Science ®Google Scholar
• Frampton JE. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 2013;73:1067-94
   PubMed Web of Science ®Google Scholar
• File TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012;55:S173-80
   PubMed Web of Science ®Google Scholar
• Hernandez PO, Lema S, Tyring SK, et al. Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist 2012;5:23-35
   PubMedGoogle Scholar
• Chambers H. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med 2014;370:2238-9
   PubMed Web of Science ®Google Scholar
• Zhanel G, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-86
   PubMed Web of Science ®Google Scholar
• Boucher H, Wilcox M, Talbot G, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014;370:2169-79
   PubMed Web of Science ®Google Scholar
• FDA approves Dalvance to treat skin infections. US Food and Drug Administration. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements.htm [Last accessed 2 July 2006]
   Google Scholar
• Prokocimer P, Bien P, Deanda C, et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56:4608-13
   PubMed Web of Science ®Google Scholar
• FDA approves Sivextro to treat skin infections. US Food and Drug Administration. Available from: http://www.fda.gov/NewsEvents/Newsroom.htm [Last Accessed 2 July 2006]
   Google Scholar
• Prokocimer P, Anda CD, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309:559-69
   PubMed Web of Science ®Google Scholar
• Moran G, Fang E, Corey G, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014;14(8):696-705
   PubMed Web of Science ®Google Scholar
• Suaya J, Mera R, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus. BMC Infect Dis 2014;14:296
   PubMed Web of Science ®Google Scholar
• Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev 2008;32:149-67
   PubMed Web of Science ®Google Scholar
• Falconer SB, Brown ED. New screens and targets in antibacterial drug discovery. Curr Opin Microbiol 2009;12:497-504
   PubMed Web of Science ®Google Scholar
• D’Elia MA, Henderson JA, Beveridge TJ, et al. The N-acetylmannosaminetransferase catalyzes the first committed step of teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 2009;191:4030-4
   PubMed Web of Science ®Google Scholar
• Brinster S, Lamberet G, Staels B, et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 2009;458:83-6
   PubMed Web of Science ®Google Scholar
• Pucci MJ, Page MGP, Bush K. Optimism for the Antibiotic Pipeline. Microbe 2014;9:147-52
   Google Scholar
• Barczak AK, Hung DT. Productive steps toward an antimicrobial targeting virulence. Curr Opin Microbiol 2009;12:490-6
   PubMed Web of Science ®Google Scholar
• Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002;418:884-993
   PubMed Web of Science ®Google Scholar
• Fairhead H. SASP gene delivery: a novel antibacterial approach. Drug News Perspect 2009;22:197-203
   PubMed Web of Science ®Google Scholar
• Noel GJ, Draper MP, Hait H, et al. A randomized, evaluator-blind, Phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56:5650-4
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012;54:S214-19
   PubMed Web of Science ®Google Scholar
• Karaoui LR, El-Lababidi R, Chahine EB. Oritavancin: an investigational lipoglycopeptide antibiotic. Am J Health Syst Pharm 2012;70:23-33
   Web of Science ®Google Scholar
• Corey G, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014;370:2180-90
   PubMed Web of Science ®Google Scholar
• Bustos C, Pozo JD. Emerging agents to combat complicated and resistant infections: focus on ceftobiprole. Infect Drug Resist 2010;3:5-14
   Google Scholar
• Barbour A, Derendorf H. Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. Ther Clin Risk Manag 2010;6:485-95
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprolemedocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55
   PubMed Web of Science ®Google Scholar
• Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Med Clin North Am 2011;95:743-60
   PubMed Web of Science ®Google Scholar
• Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: a novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 2010;67:983-93
   PubMed Web of Science ®Google Scholar
• Krievins D, Brandt R, Hawser S, et al. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother 2009;53:834-40
   Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
   PubMed Web of Science ®Google Scholar
• Nielsen SL, Black FT. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J Antimicrob Chemother 1998;42:221-6
   PubMed Web of Science ®Google Scholar
• Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999;12(Suppl 2):S45-58
   PubMedGoogle Scholar
• Craft JC, Moriarty SR, Clark K, et al. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 2011;52:S520-6
   PubMed Web of Science ®Google Scholar